

## **Pharmacogenetic Research Study in Schizophrenia Information for Physicians**

### **What is the purpose of our genetic research?**

To find genetic factors associated with weight gain/metabolic syndrome induced by antipsychotic medications (mostly clozapine, olanzapine, quetiapine and others)

To increase our understanding of interactions between neuronal and metabolic pathways

### **Do any of your patients qualify?**

We are looking for individuals with a diagnosis of schizophrenia or schizoaffective disorder

Patients must be started or be restarted/switched to an antipsychotic medication

Patients must be 18 years or older

### **What is involved?**

A two-hour interview, some questionnaires at the first visit, including a small sample of blood and saliva for genetic analysis

There will be five 30 minute visits after the first visit over a one year period

### **Compensation**

Patients will be reimbursed **\$30.00 for each study visit**

### **Confidentiality**

This study has been approved by the Ethics Committee of the Centre for Addiction and Mental Health. All information obtained during the study will remain strictly confidential

### **For more information, please contact:**

Rae Shams  
Research Trainee  
Email: [tahireh.shams@camh.ca](mailto:tahireh.shams@camh.ca)  
Phone: (416) 535 8501 ext 4347

Pharmacogenetics Research Clinic  
Centre for Addiction and Mental Health  
250 College Street  
Toronto, Ontario  
Canada M5T 1R8